Vascular ossification - Calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis - Calcific uremic arteriolopathy: The emerging role of sodium thiosulfate

Cardiovascular Diabetology

Volumn 4, Issue , 2005, Pages

  Hayden, Melvin R ^a   Tyagi, Suresh C ^b   Kolb, Lisa ^c   Sowers, James R ^a   Khanna, Ramesh ^a  

^a University of Missouri   (United States)

^b University of Louisville School of Medicine   (United States)

^c Capital City Medical Associates   (United States)

Author keywords

Atheroscleropathy; Atherosclerosis; End stage renal disease; HDL C; Lipoproteins; Oosteoatheroitis; Oxidative and redox stress; Reactive oxygen species

Indexed keywords

AMYLIN; CISPLATIN; HOMOCYSTEINE; REACTIVE OXYGEN METABOLITE; SODIUM THIOSULFATE; SOMATOMEDIN C; URIC ACID; ANTIOXIDANT; CHELATING AGENT; THIOSULFATE;

ANTIOXIDANT ACTIVITY; BLOOD VESSEL CALCIFICATION; CALCIFIC UREMIC ARTERIOLOPATHY; CALCINOSIS; CHRONIC KIDNEY DISEASE; CYANIDE POISONING; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REGIMEN; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PATHOGENESIS; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN ULCER; URIC ACID BLOOD LEVEL; VASCULAR ENDOTHELIUM; ANIMAL; ARTERY; ATHEROSCLEROSIS; CHEMISTRY; CHRONIC DISEASE; KIDNEY DISEASE; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PATHOPHYSIOLOGY; PERICYTE; PHYSIOLOGY; VASA VASORUM; VASCULAR DISEASE;

ANIMALS; ANTIOXIDANTS; ARTERIES; ATHEROSCLEROSIS; CALCINOSIS; CALCIPHYLAXIS; CHELATING AGENTS; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY DISEASES; METABOLIC SYNDROME X; OXIDATION-REDUCTION; PERICYTES; REACTIVE OXYGEN SPECIES; THIOSULFATES; VASA VASORUM; VASCULAR DISEASES;

EID: 26244446528     PISSN: 14752840     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-4-4     Document Type: Review

References (90)

1. Hayden MR, Tyagi SC: Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol 2004, 3(1):1.
2. Acierno LJ: Atherosclerosis (arteriosclerosis). In The History of Cardiology New York: Parthenon Publishing Group Inc; 1994:109-126.
3. Virchow R: Cellular Pathology: As Based Upon Physiological and Pathological Histology New York, NY: Dover; 1971.
4. Bunting C: The formation of true bone with cellular (red) marrow in a sclerotic aorta. J Exp Med 1906, 8:365-376.
5. Demer LL, Tintut Y: Mineral exploration: search for the mechanism of vascular calcification and beyond: the 2003 Jeffrey M. Hoeg Award lecture. Arterioscler Thromb Vasc Biol 2003, 23(10):1739-1743.
6. Demer LL: A skeleton in the atherosclerosis closet. Circulation 1995, 92:2029-2032.
7. Demer LL, Tintut Y: Osteopontin Between a Rock and a Hard Plaque. Circulation Research 1999, 84:250-252.
8. Giachelli CM: Vascular calcification mechanisms. J Am Soc Nephrol 2004, 15(12):2959-2964.
9. Kizu A, Jono S: [Mechanism of vascular calcification]. Clin Calcium 2004, 14(6):92-96.
10. Shioi A: [Vascular calcification]. Clin Calcium 2004, 14(6):38-41.
11. Kondos GT, Hoff JA, Sevrukov A, Daviglus ML, Garside DB, Devries SS, Chomka EV, Liu K: Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 2003, 107:2571-2576.
12. Jacoby DS, Mohler ER III, Rader DJ: Noninvasive atherosclerosis imaging for predicting cardiovascular events and assessing therapeutic interventions. Curr Atheroscler Rep 2004, 6(1):20-26.
13. Shinnar M, Fallon JT, Wehrli S, Levin M, Dalmacy D, Fayad ZA, Badimon JJ, Harrington M, Harrington E, Fuster V: The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization. Arterioscler Thromb Vasc Biol 1999, 19(11):2756-2761.
14. Tinut Y, Dermer LL: Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidology 2001, 12:555-560.
15. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM: Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000, 20(5):1262-1275.
16. Garfinkel A, Tintut Y, Petrasek D, Bostrom K, Demer LL: Pattern formation by vascular mesenchymal cells. Proc Natl Acad Sci U S A 2004, 101(25):9247-9250.
17. Abedin M, Tintut Y, Demer LL: Mesenchymal stem cells and the artery wall. Circ Res 2004, 95(7):671-676.
18. Dong C, Goldschmidt-Clermont PJ: Bone sialoprotein and the paradox of angiogenesis versus atherosclerosis. Circulation Research 2000, 86(8):827-828.
19. Hayden MR, Tyagi SC: Intimal redox stress: Accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol 2002, 1(1):3.
20. Hayden MR, Tyagi SC: Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol 2003, 2(1):2.
21. Cordain L, Eades MR, Eades MD: Hyperinsulinemic diseases of civilization: more than just Syndrome X. Comp Biochem Physiol A Mol Integr Physiol 2003, 136(1):95-112.
22. de Wazieres B, Wendling D, Fest T, Morin G, Dupond JL: [Bone and visceral manifestations of lipoatrophic diabetes. Apropos of a case]. Rev Rhum Mal Osteoartic 1992, 59(11):761-764.
23. Dacquin R, Davey RA, Laplace C, Levasseur R, Morris HA, Goldring SR, Medhin S, Galson DL, Zajac JD, Karsenty G: Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol 2004, 164(4):509-514.
24. Allison MA, Criqui MH, Wright CM: Patterns and risk factors for systemic calcified atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24(2):331-336.
25. Mehrotra R, Budoff M, Christenson P, Ipp E, Takasu J, Gupta A, Norris K, Adler S: Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int 2004, 66(5):2022-2031.
26. McCullough PA, Sandberg KR, Dumler F, Yanez JE: Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol 2004, 17(2):205-215.
27. Hayden MR, Tyagi SC: Isolated low high density lipoprotein-cholesterol (HDL-C): implications of global risk reduction. Case report and systematic scientific review. Cardiovasc Diabetol 2005, 4(1):1.
28. Chen NX, Moe SM: Arterial calcification in diabetes. Curr Diab Rep 2003, 3(1):28-32.
29. Aronson D, Rayfield EJ: How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002, 1(1):1.
30. Shimura E, Okuno S, Kitatani K, Kim M, Shoji T, Nakatani T, Inaba M, Nishizawa Y: Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients - importance of glycaemic control. Diabetologia 2002, 45(10):1446-1448.
31. Niskanen L, Siitonen O, Suhonen M, Uusitupa MI: Medial artery calcification predicts cardiovascular mortality in patients with NIDDM. Diabetes Care 1994, 17(11):1252-1256.
32. Everhart JE, Pettitt DJ, Knowler WC, Rose FA, Bennett PH: Medial arterial calcification and its association with mortality and complications of diabetes. Diabetologia 1988, 31(1):16-23.
33. Hayden MR, Tyagi SC: Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond) 2004, 1(1):10.
34. Tseng CH: Independent association of uric acid levels with peripheral arterial disease in Taiwanese patients with type 2 diabetes. Diabet Med 2004, 21(7):724-729.
35. Hayden MR, Tyagi SC: Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation. Nutr J 2004, 3(1):4.
36. Li J, Chai S, Tang C, Du J: Homocysteine potentiates calcification of cultured rat aortic smooth muscle cells. Life Sci 2003, 74(4):451-461.
37. Moe SM, Chen NX: Inflammation and vascular calcification. Blood Purif 2005, 23(1):64-71.
38. Ishimura E, Okuno S, Kitatani K, Maekawa K, Izumotani T, Yamakawa T, Jono S, Shoji T, Shioi A, Inaba M, Massry SG, Nishizawa Y: C-reactive protein is a significant predictor of vascular calcification of both aorta and hand arteries. Semin Nephrol 2004, 24(5):408-412.
39. Perianayagam MC, Jaber BL, Guo D, King AJ, Pereira BJ, Balakrishnan VS: Defective interleukin-10 synthesis by peripheral blood mononuclear cells among hemodialysis patients. Blood Purif 2002, 20(6):543-550.
40. Naidoo DP: The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes. Cardiovasc J S Afr 2002, 13(4):194-199.
41. Psyrogiannis A, Kyriazopoulou V, Vagenakis AG: Medial arterial calcification is frequently found in patients with microalbuminuria. Angiology 1999, 50(12):971-975.
42. NKF. K/DoQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
43. USRDS. 2004 Annual Data Report: Atlas of End Stage Renal Disease in the United States. Bethesda, MD 2004.
44. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32(5 Suppl 3):S112-S119.
45. Hayden MR, Tyagi SC: Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure. Med Sci Monit 2003, 9(7):SR35-SR52.
46. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000, 15(2):218-223.
47. Moe SM, Chen NX: Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004, 95(6):560-567.
48. Chen NX, Moe SM: Vascular calcification in chronic kidney disease. Semin Nephrol 2004, 24(1):61-68.
49. McCullough PA, Sandberg KR, Dumler F, Yanez JE: Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol 2004, 17(2):205-215.
50. Moe SM, O'Neill KD, Resterova M, Fineberg N, Persohn S, Meyer CA: Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 2004, 19(9):2387-2393.
51. Scoble JE: Atherosclerotic nephropathy. Kidney Int 1999, 56(S71):106-109.
52. Scoble JE, Maher ER, Hamilton G, Dick R, Sweny P, Moorhead JF: Atherosclerotic renovascular disease causing renal impairment - a case for treatment. Clin Nephrol 1989, 31(3):119-122.
53. Moe SM, Chen NX: Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis. Pediatr Nephrol 2003, 18(10):969-075.
54. Llach F: The evolving pattern of calciphylaxis: therapeutic considerations. Nephrol Dial Transplant 2001, 16(3):448-451.
55. Edsall LC, English JC 3rd, Patterson JW: Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 2004, 31(3):247-253.
56. Fukagawa M: Ever-changing concepts of calciphylaxis. Intern Med 2004, 43(1):7-8.
57. Pliquett RU, Schwock J, Paschke R, Achenbach H: Calciphylaxis in chronic, non-dialysis-dependent renal disease. BMC Nephrol 2003, 4(1):8.
58. Parker RW, Mouton CP, Young DW, Espino DV: Early recognition and treatment of calciphylaxis. South Med J 2003, 96(1):53-55.
59. Somorin AO, Al Harbi A, Subaity Y, Zaman AU: Calciphylaxis: case report and literature review. Afr J Med Med Sci 2002, 31(2):175-178.
60. Wilmer WA, Magro CM: Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 2002, 15(3):172-186.
61. Hess CT: Calciphylaxis: identification and wound management. Adv Skin Wound Care 2002, 15(2):64.
62. Tominaga Y: Uremic calciphylaxis syndrome: calcified uremic artheriolopathy. Intern Med 2001, 40(12):1174-1175.
63. Trent JT, Kirsner RS: Calciphylaxis: diagnosis and treatment. Adv Skin Wound Care 2001, 14(6):309-312.
64. Selye H: Calciphylaxis Chicago, University of Chicago Press; 1962.
65. Bryant JH, White WH: A case of calcification of the arteries and obliterative endarteritis associated with hydronephrosis in a child aged six months. Guy's Hospital Rep 1898, 55:17-20.
66. Rees JK, Coles GA: Calciphylaxis in man. BMJ 1969, 2:670-672.
67. Coates T, Kirkland GS, Dymock RB, Murphy BF, Brealey JK, Mathew TH, Disney AP: Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998, 32(3):384-391.
68. Anderson DC, Stewart WK, Pierce DM: Calcifying panniculitis with fat and skin necrosis in a case of uremia with autonomous hyperparathyroidism. Lancet 1968, 2:323-325.
69. Llach F: The evolving clinical features of calciphylaxis. Kidney Int Suppl 2003, 85:S122-124.
70. Cicone JS, Petronis JB, Embert CD, Spector DA: Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004, 43(6):1104-1108.
71. Hayden MR, Tyagi SC: Neural redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic neuropathy. Med Sci Monit 2004, 10(12):RA291-307.
72. Miller VM, Rodgers G, Charlesworth JA, Kirkland B, Severson SR, Rasmussen TE, Yagubyan M, Rodgers JC, Cockerill FR 3rd, Folk RL, Rzewuska-Lech E, Kumar V, Farell-Baril G, Lieske JC: Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves. Am J Physiol Heart Circ Physiol 2004, 287(3):H1115-HI124.
73. Jelic TM, Malas AM, Groves SS, Jin B, Mellen PF, Osborne G, Roque R, Rosencrance JG, Chang HH: Nanobacteria-caused mitral valve calciphylaxis in a man with diabetic renal failure. South Med J 2004, 97(2):194-198.
74. Maniscalco BS, Taylor KA: Calcification in coronary artery disease can be reversed by EDTA-tetracycline long-term chemotherapy. Pathophysiology 2004, 11(2):95-101.
75. Ciftcioglu N, McKay DS, Kajander EO: Association between nanobacteria and periodontal disease. Circulation 2003, 108(8):e58-59.
76. Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC: Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol 2000, 20(8):1926-1931.
77. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292(4):490-495.
78. Mody N, Parhami F, Sarafian TA, Demer LL: Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 2001, 31(4):509-519.
79. Watts N: Bisphosphonates, statins, osteoporosis, and atherosclerosis. South Med J 2002, 95(6):578-582.
80. McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR: Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine 2004, 23(1):1-10.
81. Soufi M, Schoppet M, Sattler AM, Herzum M, Maisch B, Hofbauer LC, Schaefer JR: Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab 2004, 89(8):3764-3768.
82. Collin-Osdoby P: Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004, 95(11):1046-10574.
83. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-2001. A 70-year-old woman with end-stage renal disease and cutaneous ulcers. N Engl J Med 2001, 345(15):1119-1124.
84. Wilmer WA, Magro CM: Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 2002, 15(3):172-186.
85. Treit M, Paredes BE, Ruegger S, Brand CU: Typical features of calciphylaxis in a patient with end-stage renal failure, diabetes mellitus and oral anticoagulation. Dermatology 2000, 200(4):356-359.
86. Srikureja W, Takahashi PY: 73-year-old woman with painful lower extremity ulcers. Mayo Clin Proc 2001, 76(7):745-748.
87. Russell R, Brookshire MA, Zekonis M, Moe SM: Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca x P product and aggressive wound care. Clin Nephrol 2002, 58(3):238-243.
88. Vassa N, Twardowski ZJ, Campbell J: Hyperbaric oxygen therapy in calciphylaxis-induced skin necrosis in a peritoneal dialysis patient. Am J Kidney Dis 1994, 23(6):878-881.
89. Pesanti EL: Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin North Am 2001, 15(3):813-832.
90. Hayden MR: Global risk reduction of reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy. Medical Hypothesis and Research 2004, 1(2/3):171-185.